1. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. (January 2022) Authors: Rubin, David T; Dotan, Iris; DuVall, Aaron; Bouhnik, Yoram; Radford-Smith, Graham; Higgins, Peter D R; Mishkin, Daniel S; Arrisi, Pablo; Scalori, Astrid; Oh, Young S; Tole, Swati; Chai, Akiko; Chamberlain-James, Kirsten; Lacey, Stuart; McBride, Jacqueline; Panés, Julian; Abdulkhakov, Rustem; Abu ... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 1(2022) Page Start: 17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. (April 2022) Authors: Danese, Silvio; Vermeire, Severine; D'Haens, Geert; Panés, Julian; Dignass, Axel; Magro, Fernando; Nazar, Maciej; Le Bars, Manuela; Lahaye, Marjolein; Ni, Lioudmila; Bravata, Ivana; Lavie, Frederic; Daperno, Marco; Lukáš, Milan; Armuzzi, Alessandro; Löwenberg, Mark; Gaya, Daniel R; Peyrin-Biroule... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 4(2022) Page Start: 294 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗